C
79.80
-0.48 (-0.60%)
| Previous Close | 80.28 |
| Open | 80.28 |
| Volume | 713,480 |
| Avg. Volume (3M) | 829,203 |
| Market Cap | 8,408,664,064 |
| Price / Earnings (TTM) | 91.72 |
| Price / Earnings (Forward) | 35.34 |
| Price / Sales | 12.49 |
| Price / Book | 12.86 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 19.55% |
| Operating Margin (TTM) | 2.17% |
| Diluted EPS (TTM) | 1.15 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | -26.00% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 3.07 |
| Operating Cash Flow (TTM) | 179.44 M |
| Levered Free Cash Flow (TTM) | 160.08 M |
| Return on Assets (TTM) | 9.18% |
| Return on Equity (TTM) | 21.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.49% |
| % Held by Institutions | 80.05% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ingalls & Snyder Llc | 30 Sep 2025 | 7,697,984 |
| Parallel Advisors, Llc | 30 Sep 2025 | 3,871,452 |
| Clearbridge Investments, Llc | 30 Sep 2025 | 1,161,828 |
| Charles Schwab Investment Management Inc | 30 Sep 2025 | 1,070,281 |
| Td Asset Management Inc | 30 Sep 2025 | 956,136 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 145.00 (HC Wainwright & Co., 81.70%) | Buy |
| Median | 142.50 (78.57%) | |
| Low | 140.00 (Canaccord Genuity, 75.44%) | Buy |
| Average | 142.50 (78.57%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 81.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Nov 2025 | 145.00 (81.70%) | Buy | 80.28 |
| 20 Oct 2025 | 145.00 (81.70%) | Buy | 78.60 | |
| Canaccord Genuity | 25 Sep 2025 | 140.00 (75.44%) | Buy | 82.73 |
| 10 Sep 2025 | 140.00 (75.44%) | Buy | 71.62 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUYER WILLIAM | - | 80.28 | -4,500 | -361,260 |
| Aggregate Net Quantity | -4,500 | |||
| Aggregate Net Value ($) | -361,260 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 80.28 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GUYER WILLIAM | Officer | 25 Nov 2025 | Sell (-) | 4,500 | 80.28 | 361,260 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |